James River Group Holdings, Inc. (JRVR) is a specialty property and casualty insurer operating through its Excess and Surplus (E&S) Lines and Specialty Admitted Insurance segments. With shares trading near $3.77 and a modest handful of analysts maintaining price targets between roughly $4.45 and $5.00, the question investors are asking is straightforward: can JRVR climb roughly 25% to reach the $4.72 central target?
The $4.72 average analyst price target reflects three active estimates gathered by S&P Global, with a low of about $4.45 and a high of $5.00. The most recent adjustments underscore the cautious tone. In August 2026, UBS trimmed its target to $4.45 from $4.75 while maintaining a Hold, and Truist Financial lowered its target to $5.00 from $6.00, also keeping a Hold. There are no Buy ratings on the stock.
That neutrality follows a series of downgrades: UBS moved from Buy to Neutral in May 2026, Citizens JMP from Outperform to Market Perform in May 2026, and Compass Point from Buy to Neutral in December 2025. The consistent thread is skepticism about how quickly underwriting profitability can normalize, even as analysts acknowledge the shares look inexpensive on book value. The $4.45–$5.00 range is narrow, reflecting a consensus that any upside depends more on execution than on multiple expansion.
JRVR last closed near $3.77, just above its 52-week low of $3.36 and roughly 48% below its 52-week high of $7.20. Reaching the $4.72 target implies upside of about 25%, which qualifies as a substantial move. The shares trade near 0.33 times book value and a P/E ratio in the single digits, so the market is pricing in continued earnings pressure rather than anticipating a quick recovery.
The path toward the target would most likely require the consolidated combined ratio to fall sustainably below 100%, meaning premium revenue begins exceeding claims and expenses. The E&S segment has historically shown stronger underwriting results than the consolidated figure, and any improvement there, alongside favorable reserve development and steadier investment income, would support a re-rating toward book value and beyond.
The 52-week low of $3.36 is the most important nearby support level, with the shares currently trading only modestly above it. On the upside, the $4.00 level acts as a psychological barrier, while the $4.45–$5.00 analyst target band roughly coincides with a resistance zone that would need to be cleared for a durable advance. The $7.20 prior high marks the far upper boundary of the long-term range.
Analyst price targets generally reflect a research horizon of about 12 months, though individual timelines can differ. The next key event is the company's third-quarter earnings report, scheduled for November 9, 2026, with consensus expectations around $0.17 in EPS (earnings per share) on roughly $134.8 million in revenue. Investors should watch the combined ratio, book value per share, reserve development, any guidance changes, and whether analyst ratings begin to stabilize or shift more positive.
For traders seeking a data-driven complement to fundamental research, Tickeron's AI Daily Buy/Sell Signals offer a systematic way to monitor markets. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This can help traders discover new opportunities, keep tabs on existing positions, and spot changing trends more efficiently than manual screening alone.
The $4.72 central target, derived from three analyst estimates ranging from $4.45 to $5.00, represents roughly 25% upside from a price near $3.77. The bull case rests on a discounted valuation, a strong E&S franchise, and the possibility that underwriting profitability finally normalizes. The bear case centers on a combined ratio above 100%, recent earnings misses, and a steady drumbeat of downgrades. With the stock near its 52-week low, reaching $4.72 is plausible only if execution improves measurably; the next earnings report and any change in analyst sentiment will be the clearest near-term signals of whether that path is opening.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, JRVR has been loosely correlated with FNF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if JRVR jumps, then FNF could also see price increases.
| Ticker / NAME | Correlation To JRVR | 1D Price Change % | ||
|---|---|---|---|---|
| JRVR | 100% | -14.72% | ||
| FNF - JRVR | 37% Loosely correlated | -1.93% | ||
| FAF - JRVR | 32% Poorly correlated | -1.53% | ||
| EIG - JRVR | 32% Poorly correlated | +0.84% | ||
| AGO - JRVR | 31% Poorly correlated | +0.20% | ||
| AMSF - JRVR | 29% Poorly correlated | +1.32% | ||
More | ||||